



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,

VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/06

23rd April, 2026

**Corporate Relationship Department
BSE Limited**

Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

**Listing Department
National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Investor Presentation

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors' Presentation of the Gujarat Themis Biosyn Limited ('the Company') with respect to asset purchase of Sanofi's Global Anti-TB and Anti-Infective Portfolio.

Further, a copy of the same is also available on the website of the Company, viz., www.gtbl.in

Kindly take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For **Gujarat Themis Biosyn Limited**

Vineet Gawankar
Company Secretary and Compliance Officer



Gujarat Themis Biosyn Limited

Portfolio Acquisition

Agreement with Sanofi (the French-holding company of the Sanofi group) to Acquire Select Product Portfolio



Asset acquisition structured for immediate global market access after closing

13

ESTABLISHED GLOBAL BRANDS

55+

COUNTRIES REACHED

~EURO 62M

PORTFOLIO REVENUE FY 2025

DEAL STRUCTURE

- Focused on tuberculosis and anti-infectives segment
- Presence across Europe, MEA and other global markets
- Structured as an asset acquisition (Brands + MAs + Dossiers + Inventory); No transfer of manufacturing facilities or employees
- Deal worth ~ EURO 158 Million – funded by optimal mix of debt and equity
- Acquisition subject to obtaining antitrust and foreign direct investment approvals in applicable jurisdictions

ACQUISITION HIGHLIGHTS

- Immediate access to regulated and semi-regulated markets
- Asset-light model – no capex-heavy manufacturing commitment
- Established brand equity with long-standing clinical presence
- Intermediate-to-API-to-finished dosage forward integration potential
- Portfolio originated from a global innovator (Sanofi)
- Includes WHO Essential Medicines and EU Critical Drugs

Branded Generics Products Across TB & Anti-Infective Therapies to be added



KEY MOLECULES

Rifampicin

Rifapentine

Levofloxacin

MARKET PRESENCE

EUROPE

MIDDLE EAST

AFRICA

55+ COUNTRIES

PORTFOLIO METRICS

PRODUCTS IN PORTFOLIO

13

GLOBAL REACH (COUNTRIES)

55+

RETAIL CHANNEL CONTRIBUTION

~70%

FY25 REVENUE (EURO)

~62M

Driving Global Scale and Value Chain Integration after closing



Global Expansion



- Access to 55+ countries
- Strong presence in Europe & MEA
- Entry into regulated + high TB-burden markets

Forward Integration



- Complement existing fermentation strength with API and finished formulations
- Leverage in-house capabilities
- Build integrated Intermediates → API → FDF value chain

Margin Expansion



- Strong potential to improve margin profile
- Driven by API integration & cost optimization
- Additional upside from scale efficiencies

Established Brand Equity



- Sanofi-originated portfolio
- WHO Essential / EU Critical drugs
- Strong legacy and physician trust

Asset-Light Growth Model



- No manufacturing capex required
- Scalable growth via brands & distribution
- Focus on high-return capital deployment

~EURO 62M

PORTFOLIO REVENUE
FY 2025

HEALTHY GROSS MARGINS
With expansion potential going
forward

EXPECTED TO BE EPS
ACCRETIVE
Stable performance with
consistent demand

FAVOURABLE MARKET DYNAMICS

Global TB Burden

Tuberculosis remains one of the world's leading infectious disease killers, driving sustained demand for anti-TB therapies.

Antimicrobial Resistance Focus

Increasing global focus on AMR is driving demand for established, clinically-proven anti-infective molecules.

WHO / UN Initiative Support

Strong multilateral backing and procurement programs provide demand visibility and market stability.

Commenting on this initiative,
Dr. Sachin Patel,
Managing Director,
GTBL


“This acquisition would be a strategic milestone in GTBL’s evolution toward a high-margin, fermentation-based pharmaceutical platform serving many patients in multiple regions.

By leveraging our core competencies in fermentation-based product portfolio, we are transitioning toward a high-value mix that significantly improves our margin profile and operational efficiency. This move would serve as a gateway to extend our patient reach, explore and penetrate new regulated territories, establishing a truly global footprint for our specialized offerings.

Controlling the process from fermentation to the final product minimizes supply chain risks and ensures long-term profitability improvement.

With multiple levers for value creation under our direct control, this acquisition will position GTBL to deliver consistent, long-term shareholder value while reinforcing our leadership in the fermentation space and growing the impact we have in global healthcare.”

Multiple Levers to Unlock Post Closing Value



High-Burden Market Expansion

Expansion into under-penetrated markets with high tuberculosis burden — deepening commercial presence where demand fundamentals are strongest.



Lifecycle Management

Development of new formulations and additional therapeutic indications to extend product life cycles and create incremental revenue streams.



Dormant MA Reactivation

Systematic identification and reactivation of dormant marketing authorizations to unlock latent geographic and revenue potential.



Distribution Network Leverage

Leveraging the acquired portfolio's existing distribution relationships to cross-sell and scale across geographies efficiently.



Portfolio Optimization & Brand Scaling

Strategic prioritization of high-value brands and optimization of the overall portfolio to maximize margin contribution and capital efficiency.

Thank You

For further information, please contact:

Company :

Gujarat Themis Biosyn Limited

Mr. Krupesh Patel
Chief Financial Officer
krupesh.patel@themismedicare.com

www.gtbl.in

Investor Relations Advisors :

Adfactors PR Pvt. Ltd.

Mr. Rahul Trivedi
Ms. Saloni Nagvekar
rahul.trivedi@adfactorspr.com
saloni.nagvekar@adfactorspr.com

www.adfactorspr.com
